ArticlePDF Available

Purification and Refolding to Amyloid Fibrils of (His)6-tagged Recombinant Shadoo Protein Expressed as Inclusion Bodies in E. coli

Authors:
  • Institut national de recherche pour l’agriculture, l’alimentation et l’environnement

Abstract and Figures

The Escherichia coli expression system is a powerful tool for the production of recombinant eukaryotic proteins. We use it to produce Shadoo, a protein belonging to the prion family. A chromatographic method for the purification of (His)6-tagged recombinant Shadoo expressed as inclusion bodies is described. The inclusion bodies are solubilized in 8 M urea and bound to a Ni(2+)-charged column to perform ion affinity chromatography. Bound proteins are eluted by a gradient of imidazole. Fractions containing Shadoo protein are subjected to size exclusion chromatography to obtain a highly purified protein. In the final step purified Shadoo is desalted to remove salts, urea and imidazole. Recombinant Shadoo protein is an important reagent for biophysical and biochemical studies of protein conformation disorders occurring in prion diseases. Many reports demonstrated that prion neurodegenerative diseases originate from the deposition of stable, ordered amyloid fibrils. Sample protocols describing how to fibrillate Shadoo into amyloid fibrils at acidic and neutral/basic pHs are presented. The methods on how to produce and fibrillate Shadoo can facilitate research in laboratories working on prion diseases, since it allows for production of large amounts of protein in a rapid and low cost manner.
Content may be subject to copyright.
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 1 of 8
Video Article
Purification and Refolding to Amyloid Fibrils of (His)6-tagged Recombinant
Shadoo Protein Expressed as Inclusion Bodies in E. coli
Qiaojing Li1, Charles-Adrien Richard1, Mohammed Moudjou1, Jasmina Vidic1
1Virologie et Immunologie Moléculaires, INRA
Correspondence to: Jasmina Vidic at jasmina.vidic@jouy.inra.fr
URL: http://www.jove.com/video/53432
DOI: doi:10.3791/53432
Keywords: Molecular Biology, Issue 106, Shadoo, Prion Disease, Amyloid fibers, Intrinsically Disordered Protein, His-tagged Protein Purification,
Inclusion bodies, Chromatography
Date Published: 12/19/2015
Citation: Li, Q., Richard, C.A., Moudjou, M., Vidic, J. Purification and Refolding to Amyloid Fibrils of (His)6-tagged Recombinant Shadoo Protein
Expressed as Inclusion Bodies in E. coli. J. Vis. Exp. (106), e53432, doi:10.3791/53432 (2015).
Abstract
The Escherichia coli expression system is a powerful tool for the production of recombinant eukaryotic proteins. We use it to produce Shadoo, a
protein belonging to the prion family. A chromatographic method for the purification of (His)6-tagged recombinant Shadoo expressed as inclusion
bodies is described. The inclusion bodies are solubilized in 8 M urea and bound to a Ni2+-charged column to perform ion affinity chromatography.
Bound proteins are eluted by a gradient of imidazole. Fractions containing Shadoo protein are subjected to size exclusion chromatography to
obtain a highly purified protein. In the final step purified Shadoo is desalted to remove salts, urea and imidazole. Recombinant Shadoo protein
is an important reagent for biophysical and biochemical studies of protein conformation disorders occurring in prion diseases. Many reports
demonstrated that prion neurodegenerative diseases originate from the deposition of stable, ordered amyloid fibrils. Sample protocols describing
how to fibrillate Shadoo into amyloid fibrils at acidic and neutral/basic pHs are presented. The methods on how to produce and fibrillate Shadoo
can facilitate research in laboratories working on prion diseases, since it allows for production of large amounts of protein in a rapid and low cost
manner.
Video Link
The video component of this article can be found at http://www.jove.com/video/53432/
Introduction
Prion neurodegenerative diseases, which include bovine spongiform encephalopathy in cattle, scrapie in sheep and Creutzfeldt-Jakob disease
in humans, are fatal and incurable. Prion diseases are characterized by conformational changes of cellular prion protein mainly composed of α-
helices, into the cross-β-sheet enriched amyloid conformer 1,2. Cross-β-structures contain densely packed and highly ordered crystalline-like β-
sheets stabilized with hydrogen bonds 3,4. Prion amyloids can self-replicate due to the β-strands at the growing edge that provide a template for
recruiting and converting a monomeric protein unit.
According to the "protein only" hypothesis, the amyloid conformer of prion protein is the sole infectious agent. However, some other biomolecules
have been proposed to be essential to prion disorders. For instance, cell membranes are thought to be a place where conversion takes place
and some negatively charged lipids have been shown to enhance the conversion process 5,6. In addition, some proteins may also be involved
in prion pathologies. Specifically, there are two other members of the prion protein family: Doppel and Shadoo 7,8. Doppel has a relatively rigid
structure stabilized with di-sulfide bridges and fails to self-polymerize and aggregate to amyloid fibrils 9. In contrast, similar to prion protein,
Shadoo can adopt a β-sheet-enriched structure and self-associate into amyloid fibril structures. It was shown that Shadoo can fibrillate under
native conditions or upon binding negatively charged membranes 10,11. Conversion of Shadoo into amyloid-like fibers may be associated with
pathologies. Indeed, the mechanisms by which amyloid-like structures cause disease are poorly understood.
Shadoo bears a hydrophobic domain (HD) and a series of tandem Arg/Gly repeats similar to the N-terminal part of prion protein (Figure 1A). As
the N-terminal part of prion protein, Shadoo is highly positively charged and appears to be a natively unstructured protein 11,12. Shadoo seems
to be functionally related to prion disorders since it can directly bind prion protein. In addition, its expression is down regulated during prion
pathology 13,14. However, the role of Shadoo in prion disease is not yet established.
We developed a plasmid carrying the coding sequence of the mouse Shadoo gene. The plasmid was used to transform E. coli for production
of N-terminal His6 fusion Shadoo protein. This expression system is well established in our laboratory and is commonly used in our ongoing
projects 6,15,16. An important issue for expression of Shadoo is the choice of the E. coli strain. While competent BL21 bacterial strain is commonly
used for expression of recombinant proteins Shadoo was successfully expressed and purified only from the transformed SoluBL21 bacterial
strain. SoluBL21 competent E. coli is an improved mutant of BL21 host strain developed for the production of proteins whose expression in the
parent BL21 gave no detectable soluble product. High-level expression of Shadoo in SoluBL21 E. coli leads to accumulation of the protein in
inclusion bodies. As a general feature, when a non-native protein is highly expressed in E. coli, this protein tends to accumulate in insoluble
inclusion bodies. Shadoo probably aggregates through non-covalent hydrophobic or ionic interactions (or a combination of both) to highly
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 2 of 8
enriched dynamic structures formed by the protein folded to various degrees. In consequence, the purification comprises at least two steps: (i) a
selective separation of the protein from other biomolecules in a denaturation medium, and (ii) a renaturation of the purified protein using in vitro
folding techniques.
The selective separation of Shadoo was achieved in a buffer solution containing 8M urea (or alternatively 6M Guanidine-HCl). The urea removal
and the renaturation of the protein can be done by applying various protocols: (i) renaturation in an acidic pH solution to obtain an unstructured
monomeric Shadoo protein, or (ii) renaturation in a solution of pH ≥ 7 to obtain Shadoo polymerized into stable amyloid fibers with characteristic
cross-β-sheet motifs.
Protocol
1. Generation of Plasmid and Shadoo Expression
Note: The gene encoding murine Shadoo protein (Shadoo25-122), was subcloned into the expression vector
pET-28 11. This clone was transformed into E. coli SoluBL21 bacterial strain, to express Shadoo protein with a
N-terminal hexahistidine tag, (HHHHHHHHHHSSGHIDDDDKHMKGGRGGARGSARGVRGGARGASRVRVRP
APRYGSSLRVAAAGAAAGAAAGVAAGLATGSGWRRTSGPGELGLEDDENGAMGGNGTDRGVYSYWAWTSG) as explained previously 11. The
plasmid can be requested from the authors. The molecular weight of Shadoo calculated from its amino acid sequence is 12,243.2 Da.
Note: Perform all manipulations with bacteria under a laminal flow hood or close to Bunsen flame.
1. Transform competent SoluBL21 bacteria with the pET-28-His6-Shadoo plasmid, using a standard heat shock protocol. For this mix 1 to 5 µl of
the plasmid (typically 10 pg to 100 ng) into 50 µl of the bacteria in a tube. Perform the heat shock at 42 °C for 45 sec.
2. Culture transformed bacteria at 37 °C until A600 of 0.5-0.7 in Luria-Bertani medium supplemented with 40 mg/ml kanamycin (Figure 1B).
3. Induce Shadoo expression O/N by adding 240 µg/ml isopropyl-β-D-thiogalactopyranoside, ITPG, to the culture. Culture bacteria under
shaking at 150 rpm at 37 °C. Note: Typically, bacterial culture reaches A600 of 3 O/N.
Note: Transformed bacteria can be stored at -80 °C for future protein production. For this, add 10%-50% (v/v) sterile glycerol into bacterial
culture aliquots and freeze them at -80 °C.
Figure 1. Scheme of Shadoo expression construct, bacteria transformation and induction of Shadoo expression (as described in
step 1). (A) The expression construct for Shadoo encodes a hexahistidine tag fused to the N-terminus of the protein, Nt. The scheme shows
that Shadoo protein contains basic arginine/glycine repeats (green cylinder), a hydrophobic domain (HD), and a single N-glycosylation site
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 3 of 8
(CHO), followed by a C-terminus (Ct). (B) pET-28-His6-Shadoo plasmid is transformed into SoluBL21 bacteria by heat shock for 45 sec at 42 °C.
Transformed bacteria are plated on selective agar containing 40 µg/ml kanamycin. A single colony from the plate is used to inoculate a culture
in a 1,000-3,000 ml shaker flask. Expression of the recombinant protein is induced with 1 mM IPTG. Please click here to view a larger version of
this figure.
2. Purification of Shadoo Protein by Low Pressure Liquid Chromatography (LPLC)
1. Cell lysis and Inclusion bodies preparation
1. Collect the bacterial suspension and transfer it into centrifugation tubes (Figure 2).
2. Spin at 2,500 x g, for 20 min at 4 °C. Remove supernatant by decanting and resuspend pellets in 15 ml buffer (50 mM Tris, 10 mM
EDTA, pH 8 with anti-protease cocktail) for each pellet derived from 500 ml of cell culture.
Note: Resuspended pellets can be frozen and stored at -20 °C for several days. Freezing facilitates bacterial cells lysis.
3. Check the over-expression of recombinant protein using crude bacteria pellets by SDS-PAGE analysis and Coomassie staining.
1. For this, centrifuge 1 ml of bacterial culture to pellet cells. Add 100 µl Laemmli denaturation solution (277.8 mM Tris-HCl, pH 6.8,
4.4% SDS, 44.4% w/v glycerol, 0.02% bromophenol blue) to pellet and heat at 100 °C for 5 min.
2. Load 10 µl of the sample to a 12% acrylamide gel, run SDS-PAGE and visualize separated proteins by Coomassie staining.
4. Add Triton X-100 to 0.5% final concentration to the completely resuspended pellet from 2.1.2).
5. Incubate the suspension in water bath at 37 °C for 30 min.
6. Sonicate the suspension for 5 min at 6-12 microns peak-to-peak amplitude in ice-cold water to lyse bacterial cells.
7. Transfer sonicated suspension into clean 50 ml centrifugation tubes.
8. Centrifuge tubes at 15,000 x g for 15 min at 4 °C.
9. Remove supernatant by decanting and add 5 ml of the binding buffer (20 mM Tris-HCl buffer, pH 7.4, 0.5 M NaCl, 8 M Urea, 5 mM
Imidazole) per tube.
10. Place tubes on the rotating wheel O/N to completely resuspend proteins from inclusion bodies.
Figure 2. Scheme of purification of inclusion bodies (as described in step 2.1). Transformed bacteria expressing Shadoo are
harvested by centrifugation and resuspended in the lysis buffer. The suspension is incubated at 37 °C for 30 min, and then sonicated to
mechanically break bacterial cells. Sonication is done on ice to prevent sample heating. Broken cells are harvested by centrifugation and
resuspended in a buffer containing 8 M urea to solubilize proteins from inclusion bodies. Please click here to view a larger version of this
figure.
2. Ni 2+-affinity chromatography
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 4 of 8
Note: Chromatography is performed on FPLC System using a Ni2+-charged, 5 ml Sepharose chelating column (Figure 3A). All solutions are
loaded on the column with a flow rate of 1 ml/min.
1. Inject 10 ml of 0.2 M NiSO4 water solution into the Sepharose column in order to charge it with Ni2+-ions.
2. Equilibrate the column charged with Ni2+-ions by injecting 30-50 ml of the binding buffer containing a low concentration of imidazole (20
mM Tris-HCl buffer, pH 7.4, 0.5 M NaCl, 8 M Urea, 5 mM Imidazole).
3. Load the urea-solubilized proteins with a 50 ml injection loop.
4. Recover the flow-through fraction by thoroughly washing the column with 10 ml low imidazole binding buffer (20 mM Tris-HCl buffer, pH
7.4, 0.5 M NaCl, 8 M Urea, 5 mM Imidazole) in order to remove a maximum of unbound proteins from the column.
5. Wash the column with 50-100 ml of the washing buffer (20 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 8 M urea, 80 mM imidazole) to elute
proteins non-specifically bound to the column.
6. Apply a 15 min linear gradient of 80-800 mM Imidazole in the buffer containing 20 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 8 M Urea. Collect
1 ml fractions during the gradient application. Note: His-tagged-proteins are eluted with a gradient of imidazole-containing buffer (used
as a competitor).
7. Take a 8 µl aliquot of each fraction and add 4 µl 4x Laemmli denaturation solution (see 2.1.3.1). Heat solutions at 100 °C for 5 min.
8. Load 10 µl of protein size marker and 10 µl of each sample to the 12% acrylamide gel, run SDS-PAGE and visualize separated proteins
by Coomassie staining. Note: The molecular weight of Shadoo calculated form its amino acids sequence is 12,243.2 Da.
9. Pool all fractions containing Shadoo.
Figure 3. Purification procedure (as described in steps 2.2-2.4). (A) Ni2+-ions can be coordinated by histidine residues, which allows
the selective purification of polyhistidine-tagged proteins. Imidazole is used to elute the protein, through its ability to coordinate with the
Ni2+-ion and displace the bound protein. (B) Proteins of varying hydrodynamic radius that were retained on the Ni2+-column are separated
onto a size exclusion column. Proteins are eluted from the largest to the smallest ones. (C) Prior to use, fractions containing Shadoo are
pooled and desalted to remove urea, imidazole and salts. Quality control assays include SDS-PAGE/Coomassie staining, Western blotting.
Purified Shadoo can be freeze-dried. Lyophilized Shadoo is stable for months when stored at -20 °C. Please click here to view a larger
version of this figure.
3. Size exclusion chromatography
Note: A second purification step consists in the size exclusion chromatography which separates Shadoo protein from the other proteins co-
eluted during the first purification step (Figure 3B).
1. Equilibrate Superdex column of 120 ml total bed volume by injecting 250 ml of 20 mM Tris-HCl buffer, pH 7.4, 0.5 M NaCl, 8 M Urea at
the flow rate of 1.5 ml/min.
2. Load pooled fractions containing Shadoo from 2.2.9 on the equilibrated column. Collect 1 ml fractions after the column-void volume of
40 ml upon the constant flow of the above buffer.
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 5 of 8
3. Take a 10 µl aliquot of each fraction and perform a SDS-PAGE analysis and Coomassie staining as described above to find out which
fractions contain Shadoo.
4. Pool fractions containing Shadoo.
4. Desalting
Note: Desalting procedure removes salts, imidazole and urea to obtain recombinant Shadoo protein in a buffer suitable for further biophysical
and biochemical studies (Figure 3C). The same result can be obtained by dialyzing samples against the buffer.
1. Equilibrate a desalting column of 53 ml with 150 ml of 10 mM ammonium acetate buffer, pH 5, at flow rate of 5 ml/min.
2. Load pooled Shadoo fractions on the column. Upon injection of the ammonium acetate buffer collect manually fractions that show an
increase of the signal at 280 nm at the output of the UV detector.
3. Freeze-dry the desalted Shadoo and store it at -20 °C.
4. Dissolve lyophilized Shadoo in an adequate buffer, such as 10 mM sodium acetate buffer, pH 5, prior to use.
Note: The polyhistidine tag can be removed with enterokinase.
3. In Vitro Assembling of Shadoo into Amyloid Fibrils at Physiological pH
Note: The Shadoo protein aggregates and spontaneously forms fibrils at pH ≥ 7 11.
Figure 4. Scheme of Shadoo refolding to amyloid fibrils (as described in step 3). Purified Shadoo spontaneously converts to amyloid fibrils
when dissolved in buffer of pH ≥ 7. In an acidic solution, Shadoo converts to amyloid fibrils upon incubation with 1 M Gdn-HCl while shaking.
Quality control assays include electronic microscopy and ThT staining. Please click here to view a larger version of this figure.
1. Dilute Shadoo to a final concentration of 2 µM in a 20 mM Tris-HCl buffer, pH 7.4. Measure the concentration by measuring the optical density
of the solution at 280 nm and using the extinction coefficient deduced from Shadoo amino acid composition of 20,970.
2. Incubate 500 µl of the solution in a conical plastic tube at 4 °C for a couple of weeks, to allow spontaneous protein conversion to amyloid
structures (Figure 4).
3. Add freshly prepared thioflavin T (ThT) to a final concentration of 10 µM to a 100 µl aliquot of the Shadoo solution. Incubate the solution for
5 min at RT. Measure fluorescence emission from 460 to 520 nm using an excitation wavelength of 435 nm to verify the presence of amyloid
structures 17.
4. In Vitro Assembling of Shadoo to Amyloid Fibrils at Acidic pHs
1. Dilute Shadoo in 1 M GdnHCl, 20 mM Na-acetate buffer, pH 5 to a final concentration of 2 µM.
2. Incubate 500 µl of this solution in a conical tube with continuous shaking at 37 °C, for 3-7 days.
3. Check the presence of amyloid fibrils by adding ThT to an aliquot of the solution as in 3.3.
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 6 of 8
4. Dialyze obtained suspension against 10 mM Na-acetate buffer, pH 5.0, to purify Shadoo amyloid fibrils.
5. Store purified fibrils at +4 °C.
Figure 5. Representative results. Protein fractions eluted from Ni2+-charged chelating column (A) and size exclusion column (B) were analyzed
using SDS-PAGE and Coomassie staining. Identification of purified Shadoo was assessed using SPRN anti-Shadoo antibody (C). Please click
here to view a larger version of this figure.
Representative Results
About 5-10 mg of purified Shadoo protein is obtained per liter of bacterial culture. A two-step purification is needed to obtain recombinant Shadoo
of high purity. The first step is performed by affinity chromatography with a Ni2+-charged column that retains His-tagged-proteins. Eluted fractions
are subjected to SDS-PAGE and stained with Coomassie Brilliant Blue (Figure 5A). Fractions containing Shadoo protein are pooled and further
purified by size-exclusion chromatography which separates proteins according to their size (Shadoo molecular weight is about 12 kDa). Fractions
collected upon elution are visualized by SDS-PAGE/Coomassie analysis (Figure 5B). In addition, Shadoo is evidenced by Western-blot using a
specific anti-Shadoo antibody, SPRN that binds to a sensitive epitope between 76-105 amino acids from the protein C-terminal region (Figure
5C).
Shadoo refolding to amyloid fibrils is verified by ThT staining (Figure 6A) and by negative staining electron microscopy (Figure 6B). ThT is a
fluorescent dye which binds cross-β-sheet quaternary structures characteristic for amyloid assemblies. Increase in the ThT intensity in Figure 6A
indicates that Shadoo is converted to amyloidal structures.
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 7 of 8
Figure 6. Representative results. (A) Shadoo fibrils of 2 µM monomer equivalent concentration were preincubated with ThT (10 µM final
concentration) for 5 min at RT. Fluorescent emission intensities are recorded for each sample using an excitation wavelength at 435 nm. Note a
significant increase in ThT fluorescence intensity in a solution containing Shadoo polymerized to amyloid fibrils compared to the control solution
of monomeric Shadoo. (B) Transmission electron microscopy of fibrillated Shadoo. Please click here to view a larger version of this figure.
Discussion
An easy and efficient protocol for both expression and purification of a large amount of recombinant mouse Shadoo protein is presented. The
method described allows successful solubilization and purification of (His6)-tagged recombinant Shadoo protein. It is important, as pointed
out in the title, that when expressed in a prokaryotic bacterium E. coli Shadoo accumulates in inclusion bodies. Prior to Shadoo purification,
bacteria have to be lysed by sonication in a buffer containing Triton X-100. Subsequently inclusion bodies can be solubilized in 8 M urea
denaturing solution. Further, the whole purification procedure has to be performed in 8 M urea buffer solution since Shadoo tends to polymerize
and aggregate. After solubilization and clarification of inclusion bodies, the supernatant containing denatured proteins is subjected to two-
step purification procedure: affinity chromatography and size-exclusion chromatography. The affinity chromatography step consists in binding
Shadoo via the (His6)-tag to a Ni2+-charged chelating column. In 8 M urea solution proteins are denatured and their histidine residues are
surface-exposed. In addition, urea promotes Shadoo structural integrity by preventing proteolysis in the event of contaminating proteases. In the
second purification step, Shadoo eluted from with the gradient of imidazole is subjected to size-exclusion chromatography in order to separate
contaminant proteins. During the second step, large proteins are eluted first, as they are unable to enter the pores of the matrix and, thus, have
a direct path through the column. Smaller proteins, as Shadoo, take longer to elute from the column since they can enter the pores and have a
more convoluted path. Finally, the protein preparation is desalted to remove urea, imidazole and salts. Quality control indicates that following this
procedure recombinant Shadoo is purified to high purity. It can be utilized in various biological and biotechnological studies.
The E. coli expression system is an extremely useful tool for expression of recombinant proteins. The low cost, easy manipulation, rapidity and
convenience of expressing mammalian proteins in E. coli make of this host the first choice tool for life science applications. However, not all
mammalian proteins can be expressed in soluble form or/and in a sufficient amount in this bacteria. Sometimes, obstacles may be overcome by
different strategies as lowering expression temperature, changing promoters, adding purification tags, using alternative media 18-20. However, in
some cases, finding an optimal expression condition may have a high cost in time and efforts. Difficulties to produce recombinant Shadoo were
overcome with the SoluBL21 competent E. coli strain. This mutant host strain significantly improved the yield of Shadoo production and allowed
us to obtain fully soluble Shadoo. Yields obtained were in the range 5-10 mg/L culture.
Recombinant Shadoo was shown to be a natively unstructured protein giving a random-coil feature by circular dichroism spectroscopy 11,12.
Being a highly positively charged protein (pI ~ 10.44) Shadoo tends to aggregate at the physiological pH. However, Shadoo is fully soluble
in buffer solutions of acidic pHs. We presented here simple and efficient protocols to polymerize Shadoo to amyloid fibrils at various pHs.
Polymerized Shadoo represents a valuable tool to study pathological protein foldings that characterize some neurodegenerative diseases. The
recombinant Shadoo purified using our procedure can be used for further biochemical and structural characterizations of the conformational
transition process.
Based on its primary structure, Shadoo was predicted to have one N-linked glycosylation site and signal peptides for attachment of the
glycosylphosphatidylinositol (GPI) anchor next to its C-terminus (Figure 1A). Recombinant Shadoo purified from inclusion bodies is deprived
of carbohydrates since E.coli expression system is not able to perform post-translational modifications. In consequence, interactions of
recombinant Shadoo with proteins, lipids or nucleic acids may be modified compared to the native protein. For instance, the importance of
Shadoo glycosylation was recently proposed for Shadoo proteasome degradation after protein modification by ubiquitination 21. The role of GPI
anchor in prion disease is not well known, but many studies suggest that GPI anchor may play a role in the pathogenesis of prion diseases 22,23.
Thus, bacterial expressed Shadoo can be used for in vitro studies taking into account these limitations.
Disclosures
The authors have nothing to disclose.
Journal of Visualized Experiments www.jove.com
Copyright © 2015 Journal of Visualized Experiments December 2015 | 106 | e53432 | Page 8 of 8
Acknowledgements
The authors would like to acknowledge Natalie Doude and David Westerway (University of Alberta) for providing us Sho cDNA, Christophe
Chevalier (INRA) for plasmid construction, Michel Brémont (INRA) for providing us BL21Sol bacteria; Christine Longin (INRA) for TEM
assistance and Edith Pajot-Augy (INRA) for comments and proofreading.
References
1. Biasini, E., Turnbaugh, J. A., Unterberger, U., & Harris, D. A. Prion protein at the crossroads of physiology and disease. Trends in
Neurosciences. 35, 92-103, (2012).
2. Colby, D. W., & Prusiner, S. B. De novo generation of prion strains. Nature Reviews. Microbiology. 9, 771-777, (2011).
3. Chiti, F., & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annual Review of Biochemistry. 75, 333-366, (2006).
4. Nelson, R. et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 435, 773-778, (2005).
5. Murphy, R. M. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. Biochimica et Biophysica Acta. 1768,
1923-1934, (2007).
6. Steunou, S., Chich, J. F., Rezaei, H., & Vidic, J. Biosensing of lipid-prion interactions: insights on charge effect, Cu(II)-ions binding and prion
oligomerization. Biosensors & Bioelectronics. 26, 1399-1406, (2010).
7. Watts, J. C., & Westaway, D. The prion protein family: diversity, rivalry, and dysfunction. Biochimica et Biophysica Acta. 1772, 654-672,
(2007).
8. Westaway, D., Daude, N., Wohlgemuth, S., & Harrison, P. The PrP-like proteins Shadoo and Doppel. Topics in Current Chemistry. 305,
225-256, (2011).
9. Baillod, P., Garrec, J., Tavernelli, I., & Rothlisberger, U. Prion versus doppel protein misfolding: new insights from replica-exchange molecular
dynamics simulations. Biochemistry. 52, 8518-8526, (2013).
10. Daude, N. et al. Wild-type Shadoo proteins convert to amyloid-like forms under native conditions. Journal of Neurochemistry. 113, 92-104,
(2010).
11. Li, Q. et al. Shadoo binds lipid membranes and undergoes aggregation and fibrillization. Biochemical and Biophysical Research
Communications. 438, 519-525, (2013).
12. Watts, J. C. et al. The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. The
EMBO Journal. 26, 4038-4050, (2007).
13. Watts, J. C. et al. Protease-resistant prions selectively decrease Shadoo protein. PLoS Pathogens. 7, e1002382, (2011).
14. Westaway, D. et al. Down-regulation of Shadoo in prion infections traces a pre-clinical event inversely related to PrP(Sc) accumulation. PLoS
Pathogens. 7, e1002391, (2011).
15. Chevalier, C. et al. PB1-F2 influenza A virus protein adopts a beta-sheet conformation and forms amyloid fibers in membrane environments.
The Journal of Biological Chemistry. 285, 13233-13243, (2010).
16. Tarus, B. et al. Oligomerization paths of the nucleoprotein of influenza A virus. Biochimie. 94, 776-785, (2012).
17. Biancalana, M., & Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochimica et Biophysica Acta. 1804, 1405-1412,
(2010).
18. Minic, J., Sautel, M., Salesse, R., & Pajot-Augy, E. Yeast system as a screening tool for pharmacological assessment of g protein coupled
receptors. Current Medicinal Chemistry. 12, 961-969, (2005).
19. Schein, C. H. A cool way to make proteins. Nature Biotechnology. 22, 826-827, (2004).
20. Sorensen, H. P., & Mortensen, K. K. Advanced genetic strategies for recombinant protein expression in Escherichia coli. Journal of
Biotechnology. 115, 113-128, (2005).
21. Zhang, J. et al. Disruption of glycosylation enhances ubiquitin-mediated proteasomal degradation of Shadoo in Scrapie-infected rodents and
cultured cells. Molecular Neurobiology. 49, 1373-1384, (2014).
22. Englund, P. T. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annual Review of Biochemistry. 62, 121-138,
(1993).
23. Puig, B., Altmeppen, H., & Glatzel, M. The GPI-anchoring of PrP: implications in sorting and pathogenesis. Prion. 8, 11-18, (2014).
... Refolding and aggregation are touchstones in PrP biology and, notably, natively disordered recombinant Sho (amino acids 25-122) has a propensity to aggregate to a proteaseresistant form in vitro [14,15]. Protease resistance of full-length Sho also has been reported in mammalian cells under certain conditions interfering with proteostasis [16]. ...
Article
Full-text available
The Shadoo protein (Sho) exhibits homology to the hydrophobic region of the cellular isoform of prion protein (PrPC). As prion-infected brains gradually accumulate infectivity-associated isoforms of prion protein (PrPSc), levels of mature endogenous Sho become reduced. To study the regulatory effect of the proteostatic network on Sho expression, we investigated the action of lactacystin, MG132, NH4Cl, and 3-methyladenine (3-MA) in two cell culture models. In primary mixed neuronal and glial cell cultures (MNGCs) from transgenic mice expressing wild-type Sho from the PrP gene promoter (Tg.Sprn mice), lactacystin- and MG132-mediated inhibition of proteasomal activity shifted the repertoire of Sho species towards unglycosylated forms appearing in the nuclei; conversely, the autophagic modulators NH4Cl and 3-MA did not affect Sho or PrPC glycosylation patterns. Mouse N2a neuroblastoma cells expressing Sho under control of a housekeeping gene promoter treated with MG132 or lactacystin also showed increased nuclear localization of unglycosylated Sho. As two proteasomal inhibitors tested in two cell paradigms caused redirection of Sho to nuclei at the expense of processing through the secretory pathway, our findings define a balanced shift in subcellular localization that thereby differs from the decreases in net Sho species seen in prion-infected brains. Our data are indicative of a physiological pathway to access Sho functions in the nucleus under conditions of impaired proteasomal activity. We also infer that these conditions would comprise a context wherein Sho’s N-terminal nucleic acid–binding RGG repeat region is brought into play.
Article
Full-text available
How stem cells give rise to epidermis is unclear despite the crucial role the epidermis plays in barrier and appendage formation. Here we use single cell-RNA sequencing to interrogate basal stem cell heterogeneity of human interfollicular epidermis and find four spatially distinct stem cell populations at the top and bottom of rete ridges and transitional positions between the basal and suprabasal epidermal layers. Cell-cell communication modeling suggests that basal cell populations serve as crucial signaling hubs to maintain epidermal communication. Combining pseudotime, RNA velocity, and cellular entropy analyses point to a hierarchical differentiation lineage supporting multi-stem cell interfollicular epidermal homeostasis models and suggest that transitional basal stem cells are stable states essential for proper stratification. Finally, alterations in differentially expressed transitional basal stem cell genes result in severe thinning of human skin equivalents, validating their essential role in epidermal homeostasis and reinforcing the critical nature of basal stem cell heterogeneity. The mechanisms regulating stem cells to give rise to human interfollicular epidermis are unclear. Here, the authors use single cell RNA sequencing to identify heterogeneity within the human neonatal interfollicular epidermis and distinct spatial positioning of at least four basal stem cell populations.
Article
Full-text available
The development of metastases is the major cause of cancer related death. To develop a standardized method that define the ability of human cancer cells to degrade the basement membrane, e.g. the delamination capacity, is of importance to assess metastatic aggressiveness. We now present the in vivo CAM-Delam assay to visualize and quantify the ability of human cancer cells to delaminate and invade. The method includes seeding cancer cells on the chick chorioallantoic membrane (CAM), followed by the evaluation of cancer-induced delamination and potential invasion within hours to a few days. By testing a range of human cancer cell lines in the CAM-Delam assay, our results show that the delamination capacity can be divided into four categories and used to quantify metastatic aggressiveness. Our results emphasize the usefulness of this assay for quantifying delamination capacity as a measurement of metastatic aggressiveness, and in unraveling the molecular mechanisms that regulate delamination, invasion, formation of micro-metastases and modulations of the tumor microenvironment. This method will be useful in both the preclinical and clinical characterization of tumor biopsies, and in the validation of compounds that may improve survival in metastatic cancer.
Article
The novel antimicrobial gene Hirudomacin (Hmc), with a 249-bp cDNA, encodes a mature protein of 61 amino acids and a 22-amino acid signal peptide. Hmc exhibits the highest similarity, at 90.1%, with macin family members found in the salivary gland of the leech Hirudo nipponica Whitman. A mature Hmc protein concentration of 219 μg/mL was detected using the Bradford method. The mature Hmc protein is 6862.82 Da and contains 8 cysteine residues. Antimicrobial assays showed a minimum bactericidal concentration and 50% lethal dose of 1.56 μg/mL and 0.78 μg/mL, respectively, for Staphylococcus aureus and 0.39 μg/mL and 0.195 μg/mL, respectively, for Bacillus subtilis. Transmission electron microscopy revealed membrane integrity disruption in S. aureus and B. subtilis, which resulted in bacterial lysis. The level of Hmc mRNA in the salivary gland during three blood meal stages indicated a remarkable trend of increase (P < .05), and western blotting demonstrated that among the three blood meal stages, expression of the mature Hmc protein was highest in both the salivary gland and intestine at the fed stage (P < .05). Immunofluorescence further showed the mature Hmc protein to be localized outside the cell nucleus, with the signal intensity in the salivary gland peaking at the fed stage (P < .05). In conclusion, the mature Hmc protein exhibits broad-spectrum antimicrobial effects against gram-positive and gram-negative bacteria, and a blood meal upregulates Hmc gene and protein expression in H. nipponica.
Article
Full-text available
A protocol on how to perform high-precision interdye distance measurements using Förster resonance energy transfer (FRET) at the singlemolecule level in multiparameter fluorescence detection (MFD) mode is presented here. MFD maximizes the usage of all “dimensions” of fluorescence to reduce photophysical and experimental artifacts and allows for the measurement of interdye distance with an accuracy up to ~1 Å in rigid biomolecules. This method was used to identify three conformational states of the ligand-binding domain of the N-methyl-D-aspartate (NMDA) receptor to explain the activation of the receptor upon ligand binding. When comparing the known crystallographic structures with experimental measurements, they agreed within less than 3 Å for more dynamic biomolecules. Gathering a set of distance restraints that covers the entire dimensionality of the biomolecules would make it possible to provide a structural model of dynamic biomolecules.
Article
Full-text available
Shadoo (Sho) is an N-glycosylated glycophosphatidylinositol-anchored protein that is expressed in the brain and exhibits neuroprotective properties. Recently, research has shown that a reduction of Sho levels may reflect the presence of PrP(Sc) in the brain. However, the possible mechanism by which prion infection triggers down-regulation of Sho remains unclear. In the present study, Western blot and immunohistochemical assays revealed that Sho, especially glycosylated Sho, declined markedly in the brains of five scrapie agent-infected hamsters and mice at the terminal stages. Analyses of the down-regulation of Sho levels with the emergence of PrP(Sc) C2 proteolytic fragments did not identify close association in all tested scrapie-infected models. To further investigate the mechanism of depletion of Sho in prion disease, a Sho-expressing plasmid with HA tag was introduced into a scrapie-infected cell line, SMB-S15, and its normal cell line, SMB-PS. Western blot assay revealed dramatically decreased Sho in SMB-S15 cells, especially its glycosylated form. Proteasome inhibitor MG132 reversed the decrease of nonglycosylated Sho, but had little effect on glycosylated Sho. N-acetylglucosamine transferase inhibitor tunicamycin efficiently reduced the glycosylations of Sho and PrP(C) in SMB-PS cells, while two other endoplasmic reticulum stress inducers showed clear inhibition of diglycosylated PrP(C), but did not change the expression level and profile of Sho. Furthermore, immunoprecipitation of HA-Sho illustrated ubiquitination of Sho in SMB-S15 cells, but not in SMB-PS cells. We propose that the depletions of Sho in scrapie-infected cell lines due to inhibition of glycosylation mediate protein destabilization and subsequently proteasome degradation after modification by ubiquitination.
Article
Full-text available
Lipid membrane can enhance prion protein (PrP) pathological fibrillogenesis.A neuronal paralog of PrP, namedShadoo (Sho), is localized to similar membrane environment as PrPand can also convert to amyloid-like fibrilles.To gain insight into the role of Shoin prion diseases, we studied Sho interactionswith cellular membrane models. Showas found to bind anionic lipid vesicles. Spectroscopic and microscopic data showed that membrane-associated Sho slowly converted into amyloid fibers. Furthermore, binding of Sho to anionic liposomes has a disruptive effect on the integrity of the lipid bilayer leading to the formation ofsupramolecular lipid-protein complexes. In consequence, therole of Sho in prion diseases might depend on the oligomerzation state of Shobut also the nature of theselipoproteinassembles.
Article
Full-text available
The central event in prion diseases is the conformational conversion of the cellular prion protein (PrP(C)) into PrP(Sc), a partially protease-resistant and infectious conformer. However, the mechanism by which PrP(Sc) causes neuronal dysfunction remains poorly understood. Levels of Shadoo (Sho), a protein that resembles the flexibly disordered N-terminal domain of PrP(C), were found to be reduced in the brains of mice infected with the RML strain of prions [1], implying that Sho levels may reflect the presence of PrP(Sc) in the brain. To test this hypothesis, we examined levels of Sho during prion infection using a variety of experimental systems. Sho protein levels were decreased in the brains of mice, hamsters, voles, and sheep infected with different natural and experimental prion strains. Furthermore, Sho levels were decreased in the brains of prion-infected, transgenic mice overexpressing Sho and in infected neuroblastoma cells. Time-course experiments revealed that Sho levels were inversely proportional to levels of protease-resistant PrP(Sc). Membrane anchoring and the N-terminal domain of PrP both influenced the inverse relationship between Sho and PrP(Sc). Although increased Sho levels had no discernible effect on prion replication in mice, we conclude that Sho is the first non-PrP marker specific for prion disease. Additional studies using this paradigm may provide insight into the cellular pathways and systems subverted by PrP(Sc) during prion disease.
Article
Full-text available
The influenza viruses contain a segmented, negative strand RNA genome. Each RNA segment is covered by multiple copies of the nucleoprotein (NP) and is associated with the polymerase complex into ribonucleoprotein (RNP) particles. Despite its importance in the virus life cycle, the interactions between the NP and the genome are not well understood. Here, we studied the assembly process of NP-RNA oligomers and analyzed how the oligomeric/monomeric status of RNA-free NP affects RNA binding and oligomerization. Recombinant wild-type NP purified in low salt concentrations and a derived mutant engineered for oligomerization deficiency (R416A) were mainly monomeric in RNA-free solutions as shown by biochemical and electron microscopy techniques. NP monomer formed with RNA a fast 1/1 complex characterized by surface plasmon resonance. In a subsequent and slow process that depended on the RNA length, oligomerization of NP was mediated by RNA binding. In contrast, preparations of wild-type NP purified in high salt concentrations as well as mutant Y148A engineered for deficiency in nucleic acid binding were partly or totally oligomeric in RNA-free solutions. These trimer/tetramer NP oligomers bind directly as oligomers to RNA with a higher affinity than that of the monomers. Both oligomerization routes we characterized could be exploited by cellular or viral factors to modulate or control viral RNA encapsidation by NP.
Article
Full-text available
During prion infections of the central nervous system (CNS) the cellular prion protein, PrP(C), is templated to a conformationally distinct form, PrP(Sc). Recent studies have demonstrated that the Sprn gene encodes a GPI-linked glycoprotein Shadoo (Sho), which localizes to a similar membrane environment as PrP(C) and is reduced in the brains of rodents with terminal prion disease. Here, analyses of prion-infected mice revealed that down-regulation of Sho protein was not related to Sprn mRNA abundance at any stage in prion infection. Down-regulation was robust upon propagation of a variety of prion strains in Prnp(a) and Prnp(b) mice, with the exception of the mouse-adapted BSE strain 301 V. In addition, Sho encoded by a TgSprn transgene was down-regulated to the same extent as endogenous Sho. Reduced Sho levels were not seen in a tauopathy, in chemically induced spongiform degeneration or in transgenic mice expressing the extracellular ADan amyloid peptide of familial Danish dementia. Insofar as prion-infected Prnp hemizygous mice exhibited accumulation of PrP(Sc) and down-regulation of Sho hundreds of days prior to onset of neurologic symptoms, Sho depletion can be excluded as an important trigger for clinical disease or as a simple consequence of neuronal damage. These studies instead define a disease-specific effect, and we hypothesize that membrane-associated Sho comprises a bystander substrate for processes degrading PrP(Sc). Thus, while protease-resistant PrP detected by in vitro digestion allows post mortem diagnosis, decreased levels of endogenous Sho may trace an early response to PrP(Sc) accumulation that operates in the CNS in vivo. This cellular response may offer new insights into the homeostatic mechanisms involved in detection and clearance of the misfolded proteins that drive prion disease pathogenesis.
Article
The doppel (Dpl) and prion (PrP) proteins share a very similar fold (three helices and two short β-strands), while they differ significantly in sequence (only 25% homologous) and in disease-related β-rich conformations that occur for PrP only. In a previous study [Baillod, P., et al. (2012) Biochemistry 51, 9891–9899], we investigated the misfolding and rare, β-rich folds of monomeric PrP with replica-exchange molecular dynamics (REMD) simulations. In the work presented here, we perform analogous simulations for Dpl with the aim of comparing the two systems and characterizing possible specificities of PrP for misfolding and amyloidogenesis. Our extensive simulations, which allow us to overcome high energy barriers via the REMD approach, sample several β-rich folds, some of which are stable at room temperature, for both proteins. Per residue secondary structure propensities reveal that novel β-sheets of Dpl and PrP are formed by amino acids belonging to the helices that are the least stable in the respective native structure, H1 for Dpl and H2 and H3 for PrP, in agreement with experimental data. Using a specific clustering method that allows discrimination against different β-strand arrangements, seven β-rich folds could be characterized for PrP and five for Dpl, which are clearly distinct and share only one single similar fold. A major difference between the two proteins is found in the free energy barriers leading to misfolded structures: they are approximately 3 times higher for Dpl than for PrP. This suggests that the difference in amyloidogenic behavior between PrP and Dpl might be due to kinetic reasons.
Article
The cellular prion protein (PrP(C)) is an N-glycosylated GPI-anchored protein usually present in lipid rafts with numerous putative functions. When it changes its conformation to a pathological isoform (then referred to as PrP(Sc)), it is an essential part of the prion, the agent causing fatal and transmissible neurodegenerative prion diseases. There is growing evidence that toxicity and neuronal damage on the one hand and propagation/infectivity on the other hand are two distinct processes of the disease and that the GPI-anchor attachment of PrP(C) and PrP(Sc) plays an important role in protein localization and in neurotoxicity. Here we review how the signal sequence of the GPI-anchor matters in PrP(C) localization, how an altered cellular localization of PrP(C) or differences in GPI-anchor composition can affect prion infection, and we discuss through which mechanisms changes on the anchorage of PrP(C) can modify the disease process.
Article
The presence of the cellular prion protein (PrP(C)) on the cell surface is critical for the neurotoxicity of prions. Although several biological activities have been attributed to PrP(C), a definitive demonstration of its physiological function remains elusive. In this review, we discuss some of the proposed functions of PrP(C), focusing on recently suggested roles in cell adhesion, regulation of ionic currents at the cell membrane and neuroprotection. We also discuss recent evidence supporting the idea that PrP(C) may function as a receptor for soluble oligomers of the amyloid β peptide and possibly other toxic protein aggregates. These data suggest surprising new connections between the physiological function of PrP(C) and its role in neurodegenerative diseases beyond those caused by prions.
Article
Prions are self-replicating proteins that can cause neurodegenerative disorders such as bovine spongiform encephalopathy (also known as mad cow disease). Aberrant conformations of prion proteins accumulate in the central nervous system, causing spongiform changes in the brain and eventually death. Since the inception of the prion hypothesis - which states that misfolded proteins are the infectious agents that cause these diseases - researchers have sought to generate infectious proteins from defined components in the laboratory with varying degrees of success. Here, we discuss several recent studies that have produced an array of novel prion strains in vitro that exhibit increasingly high titres of infectivity. These advances promise unprecedented insight into the structure of prions and the mechanisms by which they originate and propagate.
Article
An almost unique place within protein databases, twenty-five years of study has underscored the enigmatically subtle role of PrPC in normal cell biology. It seems that PrP has evolved (and survived) to perform a function that does not have a precedent amongst transmembrane cell-surface proteins, perhaps representing a new type of plasma membrane ecosystem. In a context where we await a clarifying insight to unify a panoply of PrPC data into logical molecular framework, the GPI-anchored N-glycosylated Doppel and Sho proteins are tantalizing in that they correspond roughly to the front and back halves of PrPC itself. These molecules may be simpler – and more “understandable” – entities that can be pursued in parallel to PrPC, and could open up the biology of mammalian prion proteins from fresh directions. Dpl has a profound role in successful gametogenesis that warrants close scrutiny and a case for deeper study can be made for Sho, a recently discovered CNS-expressed protein with many parallels to established facets of PrP biochemistry. In an aerial view of biomedical research, Sho and Dpl can be considered as adjacent islands in a prion protein archipelago. As such, the coming years of molecular exploration should be extremely interesting. Graphical Abstract